Interestingly, mutant KRAS tumours have been shown to express high constitutive levels of MKP-1, MKP-2 and MKP-3, probably as part of the regulatory feedback loop to attenuate the high activation of ERK by mutant KRAS (Bild et al, 2006). The gene discussed is DUSP1; the disease is neoplasm.